Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company’s Phase 2 clinical trial of...
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: 2024...
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
Phase 3 CSU studies initiated July 2024 Positive topline Phase 2 CIndU 12 week data reported July 2024 supporting Phase 3 advancement 52 week Phase 2 CSU data and full 12 week Phase 2 CIndU data to be...
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
July 29, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
Met primary endpoint demonstrating clinically meaningful and statistically significant complete response rate across both dose groupsFirst large, randomized, placebo-controlled study to demonstrate...
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 16, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU -- Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE)...
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 04, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024 09:01 ET
|
Celldex Therapeutics, Inc.
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
May 15, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of...
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of...